Diabetes drugs cut risk of severe COPD exacerbations: study
Researchers said that GLP-1 receptor agonists, SGLT-2 inhibitors appeared to reduce the risk of COPD exacerbations when compared with sulfonylureas
GLP-1 receptor agonists and SLGT-2 inhibitors cut the risk of exacerbations in patients with type 2 diabetes and COPD by about a third compared to sulfonylureas, new research suggests.
Although previous studies had hinted at a potential therapeutic role for these drugs in COPD, the evidence had been limited, according to researchers from McGill University in Montreal, Canada.
Their population-based cohort study used data from 43,000 patients aged 40 and over to look at whether GLP-1 receptor agonists, SGLT-2 inhibitors and DPP-4 inhibitors reduced the risk of COPD exacerbations versus sulfonylureas.
About six out of 10 participants also had a history of asthma, while half also reported moderate to severe dyspnoea.
